Open Payments

HESHAM MOHAMED ELGOUHARI

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hepatology
Where
DENISON, TX
NPI
1104096726
Received
$249,127 in 333 records, 2019 to 2025 ($147,487 general, $101,639 research)
As principal investigator
$2,350,099 of research payments to others in 161 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment55$13,517
2024General payment54$13,557
2024Research payment1$50,441
2023General payment43$13,186
2023Research payment3$1,426
2022General payment29$22,991
2022Research payment4$17,320
2021General payment40$16,051
2021Research payment2$32,452
2020General payment30$10,038
2019General payment72$58,143

By company

CompanyRecordsAmountYears
Gilead Sciences, Inc.157$112,3222019–2025
Eli Lilly and Company24$85,5272021–2024
ABBVIE INC.68$22,8322019–2025
Bausch Health US, LLC3$16,8842022
Salix Pharmaceuticals, a division of Bausch Health US, LLC38$8,1262019–2024
Mirum Pharmaceuticals, Inc.4$2,5182022–2025
Madrigal Pharmaceuticals9$2362024–2025
Ipsen Biopharmaceuticals, Inc8$1862023–2025
ORPHALAN INC6$1192024–2025
Allergan, Inc.1$862019
Intra-Sana Laboratories4$842025
Alexion Pharmaceuticals, Inc.2$552019
Shionogi Inc3$402019–2020
Intercept Pharmaceuticals, Inc.3$382019–2020
AstraZeneca Pharmaceuticals LP1$242023
Novo Nordisk Inc1$212025
Echosens North America, Inc.1$202024

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v48$122,213
Research payment10$101,639
Travel and Lodging57$15,023
Food and Beverage216$5,850
Consulting Fee1$2,400
Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing1$2,000

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-16Gilead Sciences, Inc.$3,030Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2025
2025-12-11ABBVIE INC.$14Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-12-10ORPHALAN INC$16Food and BeverageIn-kind items and servicesCUVRIOR Drug, Hepatology2025
2025-12-10Gilead Sciences, Inc.$8Food and BeverageIn-kind items and services2025
2025-12-08Gilead Sciences, Inc.$22Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2025
2025-12-01Madrigal Pharmaceuticals$33Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-11-20Gilead Sciences, Inc.$22Food and BeverageIn-kind items and services2025
2025-11-18ABBVIE INC.$32Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-11-05Madrigal Pharmaceuticals$33Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-10-24Gilead Sciences, Inc.$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2025
2025-10-23ABBVIE INC.$28Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-10-14Gilead Sciences, Inc.$7Food and BeverageIn-kind items and services2025
2025-10-14Gilead Sciences, Inc.$7Food and BeverageIn-kind items and services2025
2025-10-14Gilead Sciences, Inc.$6Food and BeverageIn-kind items and services2025
2025-10-14Gilead Sciences, Inc.$5Food and BeverageIn-kind items and services2025
2025-10-10Ipsen Biopharmaceuticals, Inc$32Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2025
2025-09-25Novo Nordisk Inc$21Food and BeverageIn-kind items and servicesWegovy Drug, Obesity2025
2025-09-24ABBVIE INC.$21Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-09-17Mirum Pharmaceuticals, Inc.$18Food and BeverageIn-kind items and servicesLivmarli Drug, Alagille syndrome2025
2025-08-19Intra-Sana Laboratories$21Food and BeverageIn-kind items and servicesRELTONE 200 MG Drug, GALLSTONES2025
2025-07-17Mirum Pharmaceuticals, Inc.$15Food and BeverageIn-kind items and servicesLivmarli Drug, Alagille syndrome2025
2025-07-10Gilead Sciences, Inc.$16Food and BeverageIn-kind items and services2025
2025-07-09Ipsen Biopharmaceuticals, Inc$17Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2025
2025-06-27ABBVIE INC.$5Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-06-18Madrigal Pharmaceuticals$26Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-06-02Gilead Sciences, Inc.$3,940Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2025
2025-05-22Gilead Sciences, Inc.$58Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2025
2025-05-20ABBVIE INC.$24Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-05-20Ipsen Biopharmaceuticals, Inc$22Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2025
2025-05-14Madrigal Pharmaceuticals$24Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-04-29Madrigal Pharmaceuticals$4Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-04-22ORPHALAN INC$21Food and BeverageIn-kind items and servicesCUVRIOR Drug, Hepatology2025
2025-04-18Gilead Sciences, Inc.$22Food and BeverageIn-kind items and services2025
2025-04-15Ipsen Biopharmaceuticals, Inc$30Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2025
2025-04-10Gilead Sciences, Inc.$14Food and BeverageIn-kind items and services2025
2025-04-07Madrigal Pharmaceuticals$16Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-03-27ABBVIE INC.$14Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-03-20Gilead Sciences, Inc.$77Travel and LodgingCash or cash equivalentEpclusa Drug, HCV2025
2025-03-20Gilead Sciences, Inc.$45Food and BeverageCash or cash equivalentEpclusa Drug, HCV2025
2025-03-20Gilead Sciences, Inc.$42Travel and LodgingCash or cash equivalentEpclusa Drug, HCV2025
2025-03-20Gilead Sciences, Inc.$6Travel and LodgingCash or cash equivalentEpclusa Drug, HCV2025
2025-03-19Intra-Sana Laboratories$23Food and BeverageIn-kind items and servicesRELTONE 200 MG Drug, GALLSTONES2025
2025-03-13Gilead Sciences, Inc.$3,240Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2025
2025-02-27ABBVIE INC.$17Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-02-22Gilead Sciences, Inc.$868Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2025
2025-02-22Gilead Sciences, Inc.$350Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2025
2025-02-22Gilead Sciences, Inc.$348Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2025
2025-02-22Gilead Sciences, Inc.$60Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2025
2025-02-22Gilead Sciences, Inc.$60Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2025
2025-02-18Intra-Sana Laboratories$22Food and BeverageIn-kind items and servicesRELTONE 200 MG Drug, GALLSTONES2025
2025-02-05Intra-Sana Laboratories$17Food and BeverageIn-kind items and servicesRELTONE 200 MG Drug, GALLSTONES2025
2025-01-30Madrigal Pharmaceuticals$17Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-01-23Gilead Sciences, Inc.$17Food and BeverageIn-kind items and services2025
2025-01-23Gilead Sciences, Inc.$16Food and BeverageIn-kind items and services2025
2025-01-21Ipsen Biopharmaceuticals, Inc$26Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2025
2024-12-20Gilead Sciences, Inc.$3,030Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2024
2024-12-17Salix Pharmaceuticals, a division of Bausch Health US, LLC$16Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-12-12Gilead Sciences, Inc.$3,940Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2024
2024-11-21ORPHALAN INC$21Food and BeverageIn-kind items and servicesCUVRIOR Drug, Hepatology2024
2024-11-20Gilead Sciences, Inc.$17Food and BeverageIn-kind items and services2024
2024-11-16Madrigal Pharmaceuticals$49Food and BeverageIn-kind items and servicesRESMETIROM Drug, LIVER DISEASE2024
2024-11-04Gilead Sciences, Inc.$114Food and BeverageIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-10-22Ipsen Biopharmaceuticals, Inc$22Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2024
2024-10-15Madrigal Pharmaceuticals$31Food and BeverageIn-kind items and servicesRESMETIROM Drug, LIVER DISEASE2024
2024-10-02ORPHALAN INC$19Food and BeverageIn-kind items and servicesCUVRIOR Drug, Hepatology2024
2024-09-30Salix Pharmaceuticals, a division of Bausch Health US, LLC$21Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-09-24Eli Lilly and Company$50,441Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON 2024
2024-09-17Gilead Sciences, Inc.$29Food and BeverageIn-kind items and services2024
2024-08-27Gilead Sciences, Inc.$16Food and BeverageIn-kind items and services2024
2024-08-18Eli Lilly and Company$186Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$169Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$93Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$70Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$56Food and BeverageIn-kind items and services2024
2024-08-18Eli Lilly and Company$51Food and BeverageIn-kind items and services2024
2024-08-18Eli Lilly and Company$32Food and BeverageIn-kind items and services2024
2024-08-18Eli Lilly and Company$23Food and BeverageIn-kind items and services2024
2024-08-18Eli Lilly and Company$23Food and BeverageIn-kind items and services2024
2024-08-18Eli Lilly and Company$13Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$13Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$13Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$6Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$5Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$4Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$4Travel and LodgingIn-kind items and services2024
2024-08-18Eli Lilly and Company$2Travel and LodgingIn-kind items and services2024
2024-08-14Gilead Sciences, Inc.$18Food and BeverageIn-kind items and services2024
2024-08-13Gilead Sciences, Inc.$12Food and BeverageIn-kind items and services2024
2024-08-13Gilead Sciences, Inc.$9Food and BeverageIn-kind items and services2024
2024-08-08Gilead Sciences, Inc.$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-08-01ABBVIE INC.$26Food and BeverageIn-kind items and servicesLINZESS Drug, GASTROENTEROLOGY2024
2024-07-29ORPHALAN INC$20Food and BeverageIn-kind items and servicesCUVRIOR Drug, Hepatology2024
2024-07-23ABBVIE INC.$16Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-07-18Ipsen Biopharmaceuticals, Inc$16Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2024
2024-07-09Salix Pharmaceuticals, a division of Bausch Health US, LLC$17Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-06-17Echosens North America, Inc.$20Food and BeverageCash or cash equivalentFibroScan Device, Elastography2024
2024-05-02Gilead Sciences, Inc.$17Food and BeverageIn-kind items and services2024
2024-04-16ABBVIE INC.$20Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-03-21Gilead Sciences, Inc.$3,240Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-03-18Salix Pharmaceuticals, a division of Bausch Health US, LLC$13Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-03-07Gilead Sciences, Inc.$13Food and BeverageIn-kind items and services2024
2024-03-02Gilead Sciences, Inc.$509Travel and LodgingIn-kind items and services2024
2024-03-02Gilead Sciences, Inc.$350Travel and LodgingIn-kind items and services2024
2024-03-02Gilead Sciences, Inc.$298Travel and LodgingIn-kind items and services2024
2024-03-02Gilead Sciences, Inc.$49Food and BeverageIn-kind items and services2024
2024-02-29ABBVIE INC.$21Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-02-15Gilead Sciences, Inc.$109Food and BeverageIn-kind items and servicesVemlidy Drug, HBV2024
2024-01-29Salix Pharmaceuticals, a division of Bausch Health US, LLC$13Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-01-18ABBVIE INC.$17Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-01-04ORPHALAN INC$20Food and BeverageIn-kind items and servicesCUVRIOR Drug, Hepatology2024
2023-12-20ABBVIE INC.$14Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-12-08Gilead Sciences, Inc.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2023
2023-12-05Gilead Sciences, Inc.$14Food and BeverageIn-kind items and services2023
2023-11-21Salix Pharmaceuticals, a division of Bausch Health US, LLC$14Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2023
2023-11-15ABBVIE INC.$18Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-11-14Gilead Sciences, Inc.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2023
2023-11-09Gilead Sciences, Inc.$17Food and BeverageIn-kind items and services2023
2023-10-18ABBVIE INC.$13Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-10-02AstraZeneca Pharmaceuticals LP$24Food and BeverageIn-kind items and services2023
2023-09-13ABBVIE INC.$11Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-08-30Salix Pharmaceuticals, a division of Bausch Health US, LLC$14Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2023
2023-08-23Ipsen Biopharmaceuticals, Inc$17Food and BeverageIn-kind items and servicesBylvay Drug, Gastroenterology2023
2023-08-16ABBVIE INC.$17Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-08-16ABBVIE INC.$7Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-08-09Gilead Sciences, Inc.$16Food and BeverageIn-kind items and services2023
2023-08-07Gilead Sciences, Inc.$6Food and BeverageIn-kind items and services2023
2023-07-25Gilead Sciences, Inc.$11Food and BeverageIn-kind items and services2023
2023-07-23ABBVIE INC.$11Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-07-20ABBVIE INC.$4Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-06-28ABBVIE INC.$22Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-06-26Salix Pharmaceuticals, a division of Bausch Health US, LLC$17Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2023
2023-06-21Salix Pharmaceuticals, a division of Bausch Health US, LLC$13Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2023
2023-06-19Gilead Sciences, Inc.$23Food and BeverageIn-kind items and services2023
2023-06-14Gilead Sciences, Inc.$20Food and BeverageIn-kind items and services2023
2023-06-14ABBVIE INC.$7Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-06-02ABBVIE INC.$14Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-05-18Eli Lilly and Company$795Research paymentIn-kind items and servicesA PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT2023
2023-05-17ABBVIE INC.$5Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-04-28Eli Lilly and Company$195Research paymentIn-kind items and servicesA STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O2023
2023-03-30Salix Pharmaceuticals, a division of Bausch Health US, LLC$15Food and BeverageIn-kind items and servicesPLENVU Drug, Gastroenterology2023
2023-03-23ABBVIE INC.$13Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-03-21Gilead Sciences, Inc.$13Food and BeverageIn-kind items and services2023
2023-02-25Gilead Sciences, Inc.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2023
2023-02-25Gilead Sciences, Inc.$382Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2023
2023-02-25Gilead Sciences, Inc.$350Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2023
2023-02-25Gilead Sciences, Inc.$336Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2023
2023-02-25Gilead Sciences, Inc.$68Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2023
2023-02-25Gilead Sciences, Inc.$51Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2023
2023-02-25Gilead Sciences, Inc.$49Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2023
2023-02-25Gilead Sciences, Inc.$49Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2023
2023-02-25Gilead Sciences, Inc.$47Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2023
2023-02-23ABBVIE INC.$17Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-02-01Mirum Pharmaceuticals, Inc.$2,400Consulting FeeCash or cash equivalent2023
2023-01-31Eli Lilly and Company$436Research paymentIn-kind items and servicesA RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACE2023
2023-01-29Gilead Sciences, Inc.$12Food and BeverageIn-kind items and services2023
2023-01-19ABBVIE INC.$15Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2022-12-15ABBVIE INC.$18Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-11-10ABBVIE INC.$18Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-09-08ABBVIE INC.$15Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-08-25Bausch Health US, LLC$9,441Research paymentCash or cash equivalentXIFAXAN Drug, GastroenterologyA Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2022
2022-08-25Bausch Health US, LLC$5,528Research paymentCash or cash equivalentXIFAXAN Drug, GastroenterologyA Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2022
2022-08-25Bausch Health US, LLC$1,914Research paymentCash or cash equivalentXIFAXAN Drug, GastroenterologyA Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2022
2022-08-24Gilead Sciences, Inc.$5,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2022
2022-08-24Gilead Sciences, Inc.$2,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2022
2022-08-23Gilead Sciences, Inc.$1,648Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2022
2022-08-23Gilead Sciences, Inc.$210Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2022
2022-08-23Gilead Sciences, Inc.$124Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2022
2022-08-23Gilead Sciences, Inc.$18Food and BeverageIn-kind items and services2022
2022-08-23Gilead Sciences, Inc.$16Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2022
2022-06-30Mirum Pharmaceuticals, Inc.$84Food and BeverageIn-kind items and services2022
2022-06-14Gilead Sciences, Inc.$139Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2022
2022-06-14Gilead Sciences, Inc.$23Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2022
2022-06-14Gilead Sciences, Inc.$10Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2022
2022-05-26Gilead Sciences, Inc.$2,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-05-26ABBVIE INC.$20Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-05-20Gilead Sciences, Inc.$5,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2022
2022-05-19Gilead Sciences, Inc.$608Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2022
2022-05-19Gilead Sciences, Inc.$569Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2022
2022-05-19Gilead Sciences, Inc.$316Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2022
2022-05-19Gilead Sciences, Inc.$100Food and BeverageIn-kind items and services2022
2022-05-19Gilead Sciences, Inc.$24Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2022
2022-04-29Eli Lilly and Company$436Research paymentIn-kind items and servicesA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLA2022
2022-03-26Gilead Sciences, Inc.$3,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2022
2022-03-26Gilead Sciences, Inc.$520Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2022
2022-03-26Gilead Sciences, Inc.$350Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2022
2022-03-26Gilead Sciences, Inc.$336Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2022
2022-03-26Gilead Sciences, Inc.$49Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2022
2022-03-26Gilead Sciences, Inc.$49Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2022
2022-02-10Gilead Sciences, Inc.$17Food and BeverageIn-kind items and services2022
2021-12-15Salix Pharmaceuticals, a division of Bausch Health US, LLC$3,760Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentXIFAXAN Drug, Gastroenterology2021
2021-12-15Salix Pharmaceuticals, a division of Bausch Health US, LLC$71Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2021
2021-12-15Salix Pharmaceuticals, a division of Bausch Health US, LLC$9Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2021
2021-12-08Salix Pharmaceuticals, a division of Bausch Health US, LLC$9Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2021
2021-11-18ABBVIE INC.$23Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2021
2021-11-03Salix Pharmaceuticals, a division of Bausch Health US, LLC$11Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2021
2021-11-03Salix Pharmaceuticals, a division of Bausch Health US, LLC$1Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2021
2021-10-25Gilead Sciences, Inc.$405Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2021
2021-10-05Gilead Sciences, Inc.$53Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2021
2021-09-29Gilead Sciences, Inc.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2021
2021-09-28Gilead Sciences, Inc.$91Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2021

The latest 200 records of 333.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-17Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$1,395A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WI2025
2025-12-17Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$915A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WI2025
2025-10-27Boehringer Ingelheim International GmbHSoma Clinical Trials$73A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-09-24Boehringer Ingelheim International GmbHSoma Clinical Trials$182A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-09-02Takeda Pharmaceuticals U.S.A., Inc.SOMA CLINICAL TRIALS LLC$3,000STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI2025
2025-09-02Takeda Pharmaceuticals U.S.A., Inc.SOMA CLINICAL TRIALS LLC$14,500STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI2025
2025-08-26Boehringer Ingelheim International GmbHSoma Clinical Trials$365A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-08-26Boehringer Ingelheim International GmbHSoma Clinical Trials$73A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-08-26Boehringer Ingelheim International GmbHSoma Clinical Trials$2A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-08-26Boehringer Ingelheim International GmbHSoma Clinical Trials$2A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-08-26Boehringer Ingelheim International GmbHSoma Clinical Trials$39A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-07-28Boehringer Ingelheim International GmbHSoma Clinical Trials$73A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-07-28Boehringer Ingelheim International GmbHSoma Clinical Trials$146A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-07-23Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,246Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-07-07Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,501Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-06-24Boehringer Ingelheim International GmbHSoma Clinical Trials$39A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-06-24Boehringer Ingelheim International GmbHSoma Clinical Trials$109A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-06-05Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,122A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2025
2025-06-04Boehringer Ingelheim International GmbHSoma Clinical Trials$7,500A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-06-04Boehringer Ingelheim International GmbHSoma Clinical Trials$7,500A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-06-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-06-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,517Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-05-27Boehringer Ingelheim International GmbHSoma Clinical Trials$292A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-05-27Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$641A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION 2025
2025-04-30AstraZeneca Pharmaceuticals LPTEXAS ARTHRITIS CENTER, PA$1,396A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerab2025
2025-04-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,501Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-04-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,246Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-04-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,445Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-04-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-03-25Gilead Sciences, Inc.SOMA CLINICAL TRIALS LLC$10,950A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$5A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$39A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$620A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$139A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$151A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$5A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$39A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$620A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$139A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-03-25Boehringer Ingelheim International GmbHSoma Clinical Trials$151A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-03-11Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,490A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2025
2025-02-28Boehringer Ingelheim International GmbHSoma Clinical Trials$12A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-02-28Boehringer Ingelheim International GmbHSoma Clinical Trials$2A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-02-28Boehringer Ingelheim International GmbHSoma Clinical Trials$239A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-02-28Boehringer Ingelheim International GmbHSoma Clinical Trials$33A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-02-28Boehringer Ingelheim International GmbHSoma Clinical Trials$21A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-02-28Boehringer Ingelheim International GmbHSoma Clinical Trials$4A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-02-28Boehringer Ingelheim International GmbHSoma Clinical Trials$4A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-02-28Boehringer Ingelheim International GmbHSoma Clinical Trials$5A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-02-25Amgen Inc.SOMA CLINICAL TRIALS LLC$91,804A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Marid2025
2025-02-07Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,517Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-02-07Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-02-07Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,527Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-02-07Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-01-31AstraZeneca Pharmaceuticals LPSOMA CLINICAL TRIALS, LLC$41,286A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerab2025
2025-01-31Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$130A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O2025
2025-01-31Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$430A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT2025
2025-01-28Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$61,059A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT2025
2025-01-21Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$115,144A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION 2025
2025-01-13Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,370A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2025
2025-01-08Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,445Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-01-08Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-01-07Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$156,033A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON 2025
2024-12-23Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$2,627A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2024
2024-12-06Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-12-06Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-12-06Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-12-06Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,445Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-12-06Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,527Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-12-06Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-11-11GlaxoSmithKline, LLC.SOMA CLINICAL TRIALS LLC$521PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF2024
2024-10-25Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,599Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-09-25Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,445Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-09-04Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,445Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-08-27GlaxoSmithKline, LLC.SOMA CLINICAL TRIALS LLC$2,109PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF2024
2024-08-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-08-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-07-05Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,599Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-06-26Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,393A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2024
2024-06-24Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-06-24Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-06-24Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,527Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-06-24Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-06-05Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,246Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-06-05Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,501Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-05-24Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$76,895A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON 2024
2024-05-06Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$971A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2024
2024-05-02Eli Lilly and CompanySOMA CLINICAL TRIALS LLC$293A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON 2024
2024-05-01Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,517Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-05-01Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,445Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-05-01Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,445Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-04-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,319A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2024
2024-04-02Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,319A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2024
2024-04-01Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-04-01Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-04-01Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$409Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-03-22Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,527Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-03-08GlaxoSmithKline, LLC.SOMA CLINICAL TRIALS LLC$2,584PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF2024
2024-03-06Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,445Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024
2024-03-06Bausch Health US, LLCSOMA CLINICAL TRIALS, LLC$1,527Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Grayson CountyDenison city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Denison, TX, county Grayson County, TX, state Texas; placed by its city name.

MeasurePlace (city or town)
Denison, TX
County
Grayson County, TX
State
Texas
Population B0100325,778143,33730,188,424
Population, 2020 census P124,479135,54329,145,505
Median age B0100240.439.035.6
Under 18 B0100125.1%24.0%25.0%
65 and over B0100120.1%18.1%13.4%
Households B1100110,38655,24810,992,816
Foreign born B050026.3%7.7%17.6%
Median household income B19013$67,365$72,182$78,476
Median family income B19113$82,891$88,124$94,599
Per capita income B19301$34,603$38,174$40,752
Poverty rate B1700115.0%11.2%13.8%
Unemployment rate B230254.6%3.1%5.3%
Civilian labor force B2302511,99570,55115,233,563
Mean commute (minutes) B0801319.425.826.7
Bachelor's degree or higher B1500318.7%23.9%33.8%
Housing units B2500111,39762,13212,128,515
Owner-occupied B2500358.6%66.8%62.6%
Renters B2500341.4%33.2%37.4%
Median home value B25077$180,900$248,400$283,800
Median gross rent B25064$1,309$1,310$1,403
White, not Hispanic B0300266.5%71.1%39.1%
Black B030026.8%5.1%11.9%
Hispanic or Latino B0300216.2%16.3%39.7%
Asian B030021.2%1.5%5.5%
American Indian and Alaska Native B030020.5%0.4%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denison, TX.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.